Short Interest in Virax Biolabs Group Limited (NASDAQ:VRAX) Decreases By 97.1%

Posted by Donald Scott on May 13th, 2026

Virax Biolabs Group Limited (NASDAQ:VRAX – Get Free Report) saw a significant decrease in short interest in the month of April. As of April 30th, there was short interest totaling 143,206 shares, a decrease of 97.1% from the April 15th total of 5,006,970 shares. Based on an average daily trading volume, of 2,702,976 shares, the days-to-cover ratio is presently 0.1 days. Approximately 6.0% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

VRAX has been the topic of several recent analyst reports. Zacks Research raised Virax Biolabs Group to a “hold” rating in a research note on Tuesday, January 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Virax Biolabs Group in a research note on Wednesday, April 8th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $1.00.

View Our Latest Stock Report on Virax Biolabs Group

Virax Biolabs Group Trading Down 2.0%

Virax Biolabs Group stock traded down $0.00 during trading on Wednesday, hitting $0.14. 470,101 shares of the company were exchanged, compared to its average volume of 9,520,667. The business’s 50 day moving average is $0.17 and its 200 day moving average is $0.30. Virax Biolabs Group has a 52 week low of $0.10 and a 52 week high of $1.20.

About Virax Biolabs Group

(Get Free Report)

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.